Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare Biotechnology
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > email from rob today
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4)
•••
Post by torontotradexon Feb 03, 2021 2:58pm
260 Views
Post# 32460727

email from rob today

email from rob today
We expect that the TSXV will resume trading of Kalytera shares within the next few days.
 
They have asked Kalytera to first issue a comprehensive press release that will provide updates on the following:
  • Kalytera's program developing R-107 for vaccine resistant coronavirus and COVID-19, as well as for other RNA viruses that cause influenza and the common cold;
  • Kalytera's program developing a novel compound for treatment of chronic pain;
  • Kalytera's Net Tangible Assets and working capital;
  • Kalytera's near-term financing plans;
  • Kalytera's plans to settle certain indebtedness; and
  • The date of Kalytera next AGM
We have sent the draft comprehensive press release to TSXV for their review and approval, and will issue it after we receive such approval. After the press release goes out, we believe the shares will resume trading.
 
Regards,
 

Robert E. Farrell

President and CEO 

Kalytera Therapeutics, Inc. 

Mobile Phone: 415-218-3900


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities